News Releases Year None20232022202120202019201820172016 Sep 05, 2023 Leap Therapeutics to Participate at Upcoming Investor Conferences Aug 14, 2023 Leap Therapeutics Reports Second Quarter 2023 Financial Results Jul 12, 2023 Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients Jun 20, 2023 Leap Therapeutics Announces Reverse Stock Split May 25, 2023 Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting May 15, 2023 Leap Therapeutics Reports First Quarter 2023 Financial Results Apr 26, 2023 Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting Apr 12, 2023 Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Mar 24, 2023 Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results Mar 16, 2023 Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 Current page 1 Page 2 Next page › Last page »
